These findings identify TSC1 as both a prognostic biomarker and a mechanistic bridge between metabolism and immune regulation, providing a conceptual and experimental foundation for the rational design of mTOR-targeted and immune checkpoint–based combination therapies in colorectal cancer. The gene discussed is MTOR; the disease is colorectal cancer.